Clinical trial
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer…
NCT00454779 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00454779 |
|---|---|
| Title | PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response |
| Official title | A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy… |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck |
| Intervention type | Drug |
| Interventions | Cisplatin, Panitumumab, Docetaxel |
| Enrollment | 113 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 11, 2012 |
| Completion | Jan 1, 2014 |
| First posted | Apr 2, 2007 |
| Last update posted | Oct 17, 2018 |
| Countries | Austria, Belgium, Czechia, France, Lithuania, Puerto Rico, Slovakia, Spain, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: